Garnet Biotherapeutics
Cell therapy company specializing in dermal-based regenerative therapy
About Garnet Biotherapeutics
Garnet Biotherapeutics, Inc. was a clinical-stage regenerative medicine company founded in 2000, initially named Neuronyx, Inc. Based in Malvern, Pennsylvania, the company focused on developing cell-based therapies to accelerate healing and minimize scarring following surgical and dermatological procedures.
The company's core technology centered on a proprietary platform for developing adult bone marrow-derived stromal cells (ABM-SCs). Researchers at Garnet claimed to have identified a specific population of these cells capable of reducing inflammation and promoting tissue repair. The lead product candidate, GBT009, was a cell-based therapy designed for topical or internal administration to release anti-inflammatory and pro-healing factors. The initial target market was cosmetic and dermatologic applications, such as post-surgical wound care for procedures like breast augmentation, with an estimated market opportunity exceeding $1 billion. The company also saw potential applications for its technology in treating burns, chronic wounds, and autoimmune disorders like psoriasis.
Between its founding and 2008, the company, as Neuronyx, Inc., raised and spent approximately $45 million on cell development and cardiac-related research without achieving commercial success. In 2008, a significant shift occurred with a change in management and a new strategic focus on post-surgical wound repair. This pivot was supported by a Series A funding round of $10.4 million in January 2009, led by SCP Vitalife and including investors like Alliance Technology Ventures and Safeguard Scientifics. This capital was intended to finance Phase II clinical trials for GBT009. However, the company was a development-stage enterprise and wholly dependent on investor funding, having generated no commercial revenue throughout its history. In late 2010, after a potential new funding round fell through due to investor disagreement over the company's future direction, Garnet faced a severe liquidity crisis. This led to the company filing for Chapter 11 bankruptcy protection on December 28, 2010. Although Garnet emerged from bankruptcy in May 2011 after a plan of reorganization, it ultimately ceased operations and is now considered deadpooled.
Source: Dealroom company dataNews
Open roles
Garnet Biotherapeutics in the Malvern ecosystem
The Garnet Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- AVAlliance Technology Ventures
- SPSCP Vitalife Partners
Safeguard Scientifics
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Garnet Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Garnet Biotherapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.